| ASSET | YEAR | % RETURN |
|---|---|---|
Erasca (ERAS) | 2026 | 408.63% |
MaxLinear (MXL) | 2026 | 382.61% |
Ichor (ICHR) | 2026 | 362.79% |
Bandwidth (BAND) | 2026 | 353.9% |
Immunitybio (IBRX) | 2026 | 335.64% |
Penguin Solutions (PENG) | 2026 | 294.72% |
Ultra Clean (UCTT) | 2026 | 286.04% |
AXT (AXTI) | 2026 | 249.53% |
Veradermics (MANE) | 2026 | 247.79% |
Tango Therapeutics (TNGX) | 2026 | 246.21% |
Definium Therapeutics (DFTX) | 2026 | 235.7% |
Silicon Motion Technology (SIMO) | 2026 | 233.31% |
Enliven Therapeutics (ELVN) | 2026 | 227.74% |
Aehr Test Systems (AEHR) | 2026 | 222.98% |
Applied Opt (AAOI) | 2026 | 214.87% |
Sellas Life Sciences (SLS) | 2026 | 209.21% |
Alumis (ALMS) | 2026 | 204.4% |
Spyre Therapeutics (SYRE) | 2026 | 191.21% |
BlackBerry (BB) | 2026 | 191.1% |
Iridium Communications (IRDM) | 2026 | 190.8% |
Vishay Intertechnology (VSH) | 2026 | 186.6% |
P3 Health Partners (PIII) | 2026 | 185.03% |
Twist Bioscience (TWST) | 2026 | 181.69% |
Oruka Therapeutics (ORKA) | 2026 | 178.46% |
Maase (MAAS) | 2026 | 159.81% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.